{"url_path":"/sec/ions/8-k/2026-07-09/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-028092-index.html","accession_number":"0001140361-26-028092","cik":"0000874015","ticker":"IONS","issuer_name":"IONIS PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/874015/0001140361-26-028092-index.html","primary_entity_key":"0000874015","primary_entity_name":"IONIS PHARMACEUTICALS INC"},"word_count":152,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\n \n\nOn July 9, 2026, Ionis Pharmaceuticals, Inc.  (“Ionis”) issued a press release announcing that the\nCARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (“ATTR-CM”) did not meet the primary efficacy endpoint of the composite outcome\nof cardiovascular (“CV”) mortality and recurrent CV clinical events up to Week 140 compared with placebo. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on\nForm 8-K.\n\n \n\nThe information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as\namended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as\namended, or the Exchange Act, regardless of any general incorporation language in such filing."}